Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Inclusion Criteria:

* Patient aged ≥55 years old
* With newly diagnosed ALL without prior treatment
* Capable to receive polychemotherapy (World Health Organization (WHO) performance status ≤2)
* With or without meningeal disease
* Having signed an Informed Consent Form
* Subscribed to social security insurance

Exclusion Criteria:

* ALL translocation(9;22) and/or BCR-ABL (Breakpoint Cluster Region-Abelson) positive
* Performance status incompatible with chemotherapy treatment (WHO score \>2)
* Patient presenting with a general or visceral contraindication to intensive treatment including :

  * Cardiac insufficiency defined as Left Ventricular Ejection Fraction \<50% of the theoretical value
  * Plasma creatinine concentration 2 times greater than the upper limit of laboratory ranges, except if related to ALL
  * Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) levels 5 times greater than the upper limit of laboratory ranges, except if related to ALL
  * Patient with another evolutive cancer other than ALL
  * Severe evolutive infection, or Human Immunodeficiency Virus (HIV) seropositive or, active hepatitis related to B or C viral infection
* Prior treatment with L-asparaginase (irrespective of the form)
* History of grade 3 transfusional incident (life threatening)
* Patient presenting rare and/or dangerous anti-erythrocyte antibodies thus leading to the unavailability of phenotype compatible Red Blood Cells Concentrate
* Patient included in another clinical trial during the last 4 weeks